Circassia to take up full US rights on Tudorza

11 December 2018
2019_biotech_test_vial_discovery_big

UK biotech firm Circassia Pharmaceuticals (LSE: CIR) today announced that it is exercising its option to acquire the full US commercial rights to Tudorza (aclidinium) from AstraZeneca (LSE: AZN).

Circassia currently promotes the chronic obstructive pulmonary disease (COPD) treatment in the USA under a profit share arrangement established by the two companies in April 2017. Circassia anticipates completing the option exercise on December 31, 2018.

Following the news, Circassia’s shares closed down 5.61% at 62.30 pence, while AstraZeneca’s shares were up 1.90% at £61.21.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology